Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, today announced the availability of Mindpeak’s AI algorithms for IHC biomarker quantification in the Paige Platform. Mindpeak, a leader in image analysis AI software, brings state-of-the-art AI algorithms for analyzing IHC slides of lung and breast tissue into the Paige Platform. These two leading pathology AI providers have combined their technologies to help pathologists deliver faster, more accurate, and more reproducible quantitative cancer diagnoses, even in the most challenging and complex cases.
This new integration allows a complete and seamless workflow on the Paige Platform through FullFocus®, Paige’s FDA-cleared whole-slide image viewer*. The viewer provides case reviewing capabilities and access to AI, including Mindpeak’s quantitative immunohistochemistry (IHC) products that enable detection, classification, and quantification of immunolabeling results for lung (PD-L1) and breast (HER2, Ki-67, ER and PR) cancers.
“The Paige Platform is one of the most robust and easily integrated solutions available for both routine and AI-augmented digital workflows. The platform offers open compatibility with Mindpeak’s image analysis algorithms and AI solutions to support a complete and optimized workflow experience for pathologists,” said Felix Faber, CEO of Mindpeak. “Providing access to real-time results for breast and lung cancer IHC biomarkers enhances efficiency and accuracy of diagnosis and treatment planning to benefit pathologists, oncologists and patients, alike.”
“The Paige and Mindpeak integration highlights the Platform’s native AI deployment capabilities and provides real-time quantitative results for routine IHC biomarkers in lung and breast cancer,” said Dr. David Klimstra, Co-Founder and Chief Medical Officer of Paige. “The seamless integration into FullFocus allows pathologists to review all images from patients’ cases and immediately view results from Mindpeak’s AI-algorithms through a single interface at the slide-level or on regions of interest selected by the pathologist, improving day-to-day workflows without the need for multiple viewers and helping pathologists reproducibly quantify the expression of key predictive markers.”